161 related articles for article (PubMed ID: 8167350)
21. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
22. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
23. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
[TBL] [Abstract][Full Text] [Related]
24. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
25. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease.
Campe H; Jaeger G; Abou-Ajram C; Nitschko H; Griebel M; Montoya C; Klare B; Koszinowski U
Pediatr Transplant; 2003 Feb; 7(1):46-52. PubMed ID: 12581328
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
27. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
Holmes RD; Orban-Eller K; Karrer FR; Rowe DT; Narkewicz MR; Sokol RJ
Transplantation; 2002 Aug; 74(3):367-72. PubMed ID: 12177616
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
[TBL] [Abstract][Full Text] [Related]
30. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
31. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
[TBL] [Abstract][Full Text] [Related]
34. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease.
Allen U; Hebert D; Petric M; Tellier R; Tran D; Superina R; Stephens D; West L; Wasfy S; Nelson S
Clin Infect Dis; 2001 Jul; 33(2):145-50. PubMed ID: 11418872
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus infections in children after transplantation of the small intestine.
Finn L; Reyes J; Bueno J; Yunis E
Am J Surg Pathol; 1998 Mar; 22(3):299-309. PubMed ID: 9500771
[TBL] [Abstract][Full Text] [Related]
36. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization.
Rose C; Green M; Webber S; Kingsley L; Day R; Watkins S; Reyes J; Rowe D
J Clin Microbiol; 2002 Jul; 40(7):2533-44. PubMed ID: 12089275
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
38. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
[TBL] [Abstract][Full Text] [Related]
39. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus.
Lones MA; Shintaku IP; Weiss LM; Thung SN; Nichols WS; Geller SA
Hum Pathol; 1997 May; 28(5):533-9. PubMed ID: 9158700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
